Table 5: Effects on physical safety indicators (X ± SD).
|
Treatment |
Baseline |
4 weeks |
8 weeks |
12 weeks |
|
|
Bodyweight (kg) |
|||
|
Policosanol |
72.2 ± 14.9 |
72.1 ± 14.9 |
72.1 ± 14.9 |
72.1 ± 14.8 |
|
Placebo |
72.1 ± 14.6 |
72.1 ± 14.5 |
72.1 ± 14.5 |
72.1 ± 14.3 |
|
|
Body mass index (kg/m2) |
|||
|
Policosanol |
26.6 ± 4.6 |
26.6 ± 4.6 |
26.5 ± 4.6 |
26.6 ± 4.6 |
|
Placebo |
26.6 ± 4.5 |
26.5 ± 4.5 |
26.5 ± 4.4 |
26.5 ± 4.1 |
|
|
Pulse rate (beats/min) |
|||
|
Policosanol |
80 ± 5.7 |
79 ± 7.5 |
78 ± 7.1 |
78 ± 7.0 |
|
Placebo |
80 ± 6.4 |
78 ± 7.7 |
78 ± 7.3 |
79 ± 6.5 |
X mean, SD standard deviation
All within (McNemar test) and between (ANOVA) group comparisons were non-significant